-

12:33:01 AM

BCLI Stock News

BCLI - Brainstorm Cell Therapeutics, Inc.

11/14/22 7:05 AM

Nasdaq : BCLI

earnings

BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update

RHEA-AI

neutral

11/10/22 8:30 AM

Nasdaq : BCLI

BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the

RHEA-AI

neutral

11/07/22 4:10 PM

Nasdaq : BCLI

earnings

BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended

RHEA-AI

neutral

11/07/22 6:00 AM

Nasdaq : BCLI

clinical trial

BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular

RHEA-AI

neutral

10/20/22 6:00 AM

Nasdaq : BCLI

clinical trial

BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced

RHEA-AI

neutral

10/07/22 12:00 PM

Nasdaq : BCLI

clinical trial

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

NurOwn ® drove biomarker responses, affecting pathways related to neurodegeneration, neuroinflammation, and neuroprotection, that were consistent in participants with both advanced ALS and less advanced disease, confirming the importance of accounting for ALSFRS-R floor effects when evaluating

RHEA-AI

positive

09/15/22 6:00 AM

Nasdaq : BCLI

clinical trial

BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

BrainStorm Cell Therapeutics

RHEA-AI

positive

08/15/22 7:05 AM

Nasdaq : BCLI

earnings

BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update

BrainStorm to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn ® for the treatment of ALSNew clinical analyses reinforce the conclusions from NurOwn's® Phase 3 clinical trialConference call and webcast at 8:00 a.m. Eastern Time todayNEW YORK

RHEA-AI

neutral

08/01/22 6:00 AM

Nasdaq : BCLI

earnings

BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June

RHEA-AI

neutral

05/31/22 6:00 AM

Nasdaq : BCLI

BrainStorm Announces Presentations at June 2022 Scientific Conferences

Analyses accounting for ALSFRS-R floor effect in ALS yields new results to be presented at the ENCALS meeting in Edinburgh, ScotlandClinical, biomarker and preclinical data from NurOwn® Phase 2 clinical trial in MS to be presented at CMSC meeting in National Harbor, MD, USANEW YORK , May 31, 2022

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

BCLI Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.brainstorm-cell.com
CeoChaim Lebovits
Security nameBrainstorm Cell Therapeutics, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees40
Tags
- Electronic Technology
- Computer Peripherals
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address1325 Avenue of the Americas Fl 28
StateNew York
CityNew York
Zip10019-6583
CountryUS
Phone12014880460

About Brainstorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm is also conducting an FDA-approved Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing in December 2020, and topline results are expected by the end of the first quarter 2021.